Table 1 Disease characteristics among patients who received radiotherapy during their treatment course (RT) and who didn’t (Non-RT), as well as in the whole population
|
ALL patients n (%) |
Non-RT n (%) |
RT n (%) | p | |
|---|---|---|---|---|
| Age (years) | 0.958 | |||
| Median | 50 | 49 | 50 | |
| Range | 21–75 | 28–75 | 21–68 | |
| Sex | 0.079 | |||
| Male | 55 (59.1) | 26 (51.0) | 29 (69.0) | |
| Female | 38 (40.9) | 25 (49.0) | 13 (31.0) | |
| Histology | 0.452 | |||
| Adenocarcinoma | 90 (96.8) | 50 (98.0) | 40 (95.2) | |
| Non-adenocarcinoma | 3 (3.2) | 1 (2.0) | 2 (4.8) | |
| ECOG | 0.814 | |||
| 0–1 | 88 (94.6) | 48 (94.1) | 40 (95.2) | |
| 2 | 5 (5.4) | 3 (5.9) | 2 (4.8) | |
| Primary tumor Size (cm) | 0.390 | |||
| Median | 3.5 | 3.5 | 3.0 | |
| Range | 0.0–8.0 | 0.0–8.0 | 0.0–7.9 | |
| T stage | 0.841 | |||
| T1–2 | 52 (55.9) | 29 (56.9) | 23 (54.8) | |
| T3–4 | 41 (44.1) | 22 (43.1) | 19 (45.2) | |
| N stage | 0.513 | |||
| N0 | 9 (9.7) | 4 (7.8) | 5 (11.9) | |
| N1–3 | 84 (90.3) | 47 (92.2) | 37 (88.1) | |
| Number of metastatic organs | 0.055 | |||
| 1–2 | 66 (71.0) | 32 (62.7) | 34 (81.0) | |
| ≥ 3 | 27 (29.0) | 19 (37.3) | 8 (19.0) | |
| Number of metastatic lesions | 0.053 | |||
| 1–5 | 28 (30.1) | 11 (21.6) | 17 (40.5) | |
| ≥ 6 | 65 (69.9) | 40 (78.4) | 25 (59.5) | |
| Presence of lung metastases | 0.069 | |||
| Yes | 24 (25.8) | 17 (33.3) | 7 (16.7) | |
| No | 69 (74.2) | 34 (67.7) | 35 (83.3) | |
| Presence of liver metastases | 0.119 | |||
| Yes | 15 (16.1) | 11 (21.6) | 4 (9.5) | |
| No | 78 (83.9) | 40 (78.4) | 38 (90.5) | |
| Presence of brain metastases | 0.010 | |||
| Yes | 35 (37.6) | 13 (25.5) | 22 (52.4) | |
| No | 58 (62.4) | 38 (74.5) | 20 (47.6) | |
| Presence of adrenal metastases | 0.086 | |||
| Yes | 13 (14.0) | 10 (19.6) | 3 (7.1) | |
| No | 80 (86.0) | 41 (80.4) | 39 (92.9) | |
| Presence of Bone metastases | 0.698 | |||
| Yes | 33 (35.5) | 19 (37.3) | 14 (33.3) | |
| No | 60 (64.5) | 32 (62.7) | 28 (66.7) |